Greater Weight Loss, More Side Effects: What GLP-1 RAs Mean for Women
Key Takeaways:
- Real-world studies show women treated with GLP-1 receptor agonists (GLP-1 RAs) report side effects such as headache, vomiting and dizziness more often than men, even though placebo-controlled trials suggest similar rates in both sexes.
- Women tend to lose more weight on GLP-1 RAs than men, while improvements in blood sugar control are comparable, possibly due to higher drug exposure, stronger suppression of food-motivated behaviours and interactions between GLP-1 signalling and oestrogen.
- The authors call for mandatory sex- and ethnicity-stratified trial reporting, more research across every stage of women’s lives, and equitable global access to genuine GLP-1 RAs, as nearly 80% of eligible adults live in low- and middle-income countries where access remains minimal.
A call to action on GLP-1 RA use in women
The second of a Series of papers presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (28 September – 2 October), and published in The Lancet Obstetrics, Gynaecology & Women’s Health, examines the wide-ranging issues surrounding GLP-1 RA use in women.
The authors, including Professor Paul Franks of Lund University and Helsingborg Hospital, Helsingborg, Sweden, and Professor Claire Meek of the Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK, alongside colleagues, issue a call to action to strengthen the evidence base for GLP-1 RA use in women worldwide.
The global burden of obesity among women
The prevalence of obesity is estimated to be slightly higher among women than among men, and this difference varies according to socioeconomic status. A recent analysis by the Global Burden of Disease group estimated that, in 2021, the global prevalence of overweight or obesity was 46.7% in females and 43.4% in males. Projections for 2050 rise to 60.3% and 57.4%, respectively.
This gender gap is more pronounced in low- and middle-income countries (LMICs), with the largest gaps seen in sub-Saharan Africa and south Asia. By contrast, men in high-income countries can have higher prevalence rates. The trend is likely to continue in the coming decades and is linked to socioeconomic inequalities, highlighting how broader social barriers disproportionately affect women in many regions of the world.
Why women may lose more weight on GLP-1 RAs
Weight loss with GLP-1 RAs is greater in women than in men, yet improvements in blood sugar control are comparable between the sexes. Several mechanisms could explain this greater weight-loss efficacy in women:
- Higher systemic drug exposure has been observed in women, even after adjusting for body mass.
- Women treated with GLP-1 RAs may experience enhanced suppression of food-motivated behaviours and greater inhibition of palatable food intake.
- Pre-clinical studies have highlighted possible interactions between GLP-1 signalling and oestrogen.
Side effects and weight regain
Real-world studies comparing adverse event rates in women and men treated with these medications have found a higher overall frequency of reported side effects among women, including increased rates of headache, vomiting and dizziness. This contrasts with placebo-controlled trials, which suggest similar rates in both sexes. The authors therefore stress that more studies are needed to quantify side-effect profiles in women and to develop strategies to mitigate them.
It is also well established that weight can be regained rapidly after GLP-1 RA treatment is stopped. Regaining fat without regaining additional muscle raises concerns about longer-term health and physical function in women, and further research is needed to ensure these powerful medications support women’s wellbeing over the long term.
Mental health and psychiatric safety
Trial data to date support the overall psychiatric safety profile of GLP-1 RAs, while reinforcing the importance of individualised risk assessment. Careful, routine screening for depression, anxiety and eating disorders is recommended for people of both sexes, both before treatment begins and during follow-up.
For healthcare professionals prescribing or supporting people on these medications, The College of Contemporary Health’s GLP-1RAs in Focus course offers a grounding in GLP-1 receptor agonist therapy, helping clinicians approach treatment decisions, monitoring and patient conversations with confidence.
Affordability and access in low- and middle-income countries
Independent manufacturing estimates suggest that semaglutide, for example, could be produced for less than $1 per month’s supply in oral form and $5 per month as an injection. However, recent analyses across 99 countries indicate that nearly 80% of adults who meet clinical eligibility criteria for GLP-1 RAs live in LMICs, where access remains minimal. In many of these settings, retail prices exceed $90 per month, placing treatment beyond the reach of women who rely on publicly funded care or out-of-pocket payments.
Diverse populations and polyendocrine metabolic ovarian syndrome
The paper explores multiple areas in which GLP-1 RAs affect women’s health, and highlights the need for further research in each. For example, many women with type 2 diabetes in LMICs are lean, and the BMI threshold at which type 2 diabetes begins to develop is often lower than for people of European ancestry. As a result, significant weight loss could have a more pronounced impact on these women.
Polyendocrine metabolic ovarian syndrome (PMOS; formerly polycystic ovary syndrome) affects around 12% of women worldwide, with the highest rates in the eastern Mediterranean region and south-east Asia. Although weight loss leads to various health improvements in women with PMOS, GLP-1 RAs are not generally available or centrally funded for PMOS in most healthcare systems.
Research priorities across women’s lives
The authors conclude that extensive research into GLP-1 RA use in women is needed across a range of domains, including:
- mental health and eating disorders
- contraception, fertility and polyendocrine metabolic ovarian syndrome
- optimising pre-pregnancy health
- preventing complications
- safety during pregnancy and breastfeeding
- optimising health and body composition during menopause
- optimising cardiovascular health and preventing multimorbidity
- frailty and healthy ageing
The authors’ call to action
In their call to action, the authors say:
- “Women face the highest burden of obesity and its related complications, and should have access to high-quality, equitable, multidisciplinary obesity care worldwide”
- “Sex-stratified and ethnicity-stratified reporting of clinical trials related to GLP-1 receptor agonist use should be mandatory to facilitate future meta-analyses”
- “As the main users of GLP-1 receptor agonists and incretin-based therapies, women’s care should be guided by high-quality studies assessing their treatment’s efficacy and safety, specifically in conditions affecting women (eg, before, during, and after pregnancy)”
- “Existing access pathways to GLP-1 receptor agonists disadvantage women – to maximise the treatment’s benefits, companies, health-care funders, research funders, insurers, and policy makers should promote equitable access to high-quality, genuine GLP-1 RAs for women worldwide”
The authors conclude: “Tackling the global challenges in access to GLP-1 receptor agonists provides substantial opportunities to improve women’s health internationally. However, achieving equitable access will require coordinated action to strengthen supply chains, enhance regulatory vigilance against falsified and compounded products, and embrace innovative therapies – such as oral agents – that are stable, scalable, and potentially more affordable…Advancing women-centred obesity care demands targeted research, including trials inclusive of diverse ethnic groups, women of reproductive age, and LMIC populations, alongside women-focused cost-effectiveness and implementation studies.”
CCH insight
As GLP-1 RAs become central to obesity and diabetes care, understanding how they affect different groups, including women at different life stages, is increasingly important for safe, effective prescribing. Build your knowledge with our GLP-1RAs in Focus CPD course.
Explore GLP-1RAs in Focus – Why Drugs Like Ozempic Work →
Source: European Association for the Study of Diabetes
Read More
AI Analysis of 400,000 Reddit Posts Reveals Underreported Side Effects of GLP-1 Medications
Key Takeaways:
- University of Pennsylvania researchers used artificial intelligence to analyse more than 400,000 Reddit posts from nearly 70,000 users discussing semaglutide and tirzepatide, identifying symptoms that may be underrepresented in clinical trials and official regulatory information.
- Reproductive symptoms, including menstrual irregularities, and changes in body temperature, such as chills and hot flashes, emerged as signals particularly worth investigating, alongside fatigue, which was the second most frequently reported complaint.
- The findings show associations in what people discussed online, not proof that GLP-1 medications cause these symptoms, but the researchers suggest “computational social listening” could become a fast, early detection system for emerging drug safety concerns.
Listening to patients at scale
Artificial intelligence is offering researchers a new way to hear what patients are saying about widely used GLP-1 medications. After analysing more than 400,000 Reddit posts, a team at the University of Pennsylvania identified several symptoms reported by people using semaglutide (Ozempic, Wegovy and Rybelsus) and tirzepatide (Mounjaro and Zepbound) that may not be fully reflected in clinical trials or official regulatory information.
The study, recently published in Nature Health, examined more than five years of posts from nearly 70,000 Reddit users. Two categories of symptoms stood out as particularly deserving of further investigation: reproductive symptoms, including changes to menstrual cycles, and problems relating to body temperature, such as chills and hot flashes.
Importantly, the findings do not establish that the medications caused these symptoms. Rather, the researchers say that this vast collection of spontaneous patient reports may reveal signals that merit closer examination.
“Some of the side effects we found, like nausea, are well known, and that shows that the method is picking up a real signal,” says Sharath Chandra Guntuku, Research Associate Professor in Computer and Information Science (CIS) at Penn Engineering and the study’s senior author. “The underreported symptoms are leads that came from patients themselves, unprompted, and clinicians could potentially pay attention to them.”
What patients report outside clinical trials
Clinical trials are designed to determine whether treatments work and to identify significant safety problems. However, they cannot necessarily capture every symptom that matters to patients once a medication is being used by a much larger and more varied population.
“Clinical trials generally identify the most dangerous side effects of drugs,” adds Lyle Ungar, Professor in CIS and a co-author on the study. “But they can fail to find what symptoms patients are most concerned about; even though social media is not necessarily representative, a large collection of posts may reflect additional concerns.”
This distinction is an important one. The study identified associations in what people discussed online, not evidence that GLP-1 medications were responsible for those experiences.
“We can’t say that GLP-1s are actually causing these symptoms,” notes Neil Sehgal, the study’s first author and a doctoral student in CIS advised by Guntuku and Ungar. “But nearly 4% of the Reddit users in our sample reported menstrual irregularities, which would be even higher in a female-only sample. We think that’s a signal worth investigating.”
Using social media as an early health signal
The idea of mining online conversations for clues about drug safety predates the current AI boom. In 2011, Ungar took part in one of the earliest efforts to use content created by internet users to identify possible adverse effects of medications.
Social media can capture experiences that patients discuss with one another but may never formally report to a doctor, drug manufacturer or regulator.
“Online patient communities work a lot like a neighborhood grapevine,” says Ungar. “People who are living with these medications are swapping notes with each other in real time, sharing experiences that rarely make it into a doctor’s office visit or an official report.”
Since then, online patient communities have grown enormously. This has made social media a potentially valuable source for understanding how medications affect people in everyday life, although gaining access to platform data has become more difficult.
The researchers emphasise that traditional clinical research remains essential, but online conversations can provide information far more quickly when millions of people begin using a medication.
“Clinical trials are the gold standard, but by design, they are slow,” says Guntuku. “This is not a replacement for trials, but it can move much faster, and that speed matters when a drug goes from niche to mainstream almost overnight.”
How AI makes large-scale analysis possible
One of the biggest obstacles to this kind of research has always been scale.
Guntuku describes the approach as “computational social listening”, which uses computational methods to identify patterns across large collections of online conversations about health.
Patients, however, rarely describe their symptoms using standardised medical terminology. One person might describe feeling unusually cold, another might mention constant chills, while a clinician could categorise both experiences using a specific medical term.
Researchers therefore need a way to translate everyday language into standardised categories. One important reference is the Medical Dictionary for Regulatory Activities (MedDRA), which provides terminology widely used to classify medical conditions, symptoms and adverse events.
Previously, matching vast numbers of informal social media posts to standardised medical terminology required an enormous amount of work, limiting how much data researchers could realistically analyse.
Large language models such as GPT and Gemini are changing that, allowing researchers to process and categorise huge volumes of text more quickly and consistently.
“Large language models have made it possible to do this kind of analysis much faster with a level of standardization that could be difficult to achieve before,” says Sehgal.
Unexpected symptoms emerge from 400,000 posts
The researchers stress that Reddit users do not represent the wider population of people taking GLP-1 medications. Reddit users tend to be younger, are more likely to be male and are disproportionately based in the United States.
Despite this limitation, the analysis produced a reassuring sign that the approach was detecting genuine patterns: many of the symptoms discussed by Reddit users closely matched the already known effects of semaglutide and tirzepatide.
Around 44% of users included in the study described at least one side effect. Gastrointestinal problems were the most common, consistent with the nausea and other digestive issues already associated with these medications.
More intriguing were symptoms that appeared frequently enough to attract the researchers’ attention but may not be as well represented in current drug labels or conventional adverse event reports:
- Reproductive symptoms: nearly 4% of users who reported side effects described reproductive symptoms, including changes to menstruation such as bleeding between periods, heavy bleeding and irregular menstrual cycles.
- Body temperature changes: users described chills, feeling unusually cold, hot flashes and symptoms resembling a fever.
- Fatigue: this was the second most frequently reported complaint in the Reddit data, even though relatively few clinical trials reported fatigue often enough for it to meet established reporting thresholds.
For healthcare professionals prescribing or supporting people using these medications, findings like these are a reminder of the value of asking open questions about how patients are feeling, beyond the side effects most commonly discussed. Clinicians wishing to build confidence in this area may find The College of Contemporary Health’s GLP-1RAs in Focus CPD course a useful way to deepen their understanding of these therapies and the conversations that surround them.
Why menstrual and temperature changes are of interest
One possible reason these reports caught the researchers’ attention involves the hypothalamus, a small but vitally important region of the brain. Among its many roles, the hypothalamus helps regulate hunger, hormones, reproduction and body temperature.
“These drugs are thought to work by engaging part of the brain called the hypothalamus, which helps regulate a wide variety of hormones,” says Jena Shaw Tronieri, Senior Research Investigator at Penn’s Center for Weight and Eating Disorders and a co-author of the study. “That doesn’t mean the medications are necessarily causing these symptoms, but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically.”
The researchers are not suggesting that this biological link proves GLP-1 medications are responsible. Instead, it provides a further reason to test these patient-reported patterns more rigorously through controlled research.
Turning online conversations into research leads
For now, the team hopes the results will encourage scientists and clinicians to pay closer attention to the symptoms that patients repeatedly discuss online.
“They’re clearly on patients’ minds, and that’s worth paying attention to,” says Sehgal.
The researchers also plan to extend their analysis beyond Reddit and beyond English-language communities. Doing so could help determine whether the same patterns emerge among different groups of people and across different social media platforms.
“We don’t really know yet whether what we’re seeing on Reddit reflects the experience of GLP-1 users globally, or whether it’s particular to the kind of person who posts on Reddit in the United States,” Ungar says.
An early warning system for emerging health concerns
In the longer term, rapid AI analysis of online patient conversations could become an early detection system for emerging health concerns involving medications, supplements and wellness products.
This could be especially valuable for substances that gain popularity online faster than conventional research can keep pace. Loosely regulated or unregulated products, including injectable peptides, can spread rapidly through communities on Reddit, TikTok and other platforms, meaning that discussions among users may offer some of the earliest indications of unexpected effects.
“The whole point of this kind of approach is that it can move quickly, and that’s exactly when it’s most valuable,” says Guntuku.
The study was conducted at the University of Pennsylvania School of Engineering and Applied Science. The authors report no outside funding. Tronieri reports receiving an investigator-initiated grant, on behalf of the University of Pennsylvania, from Novo Nordisk, and receiving consulting fees from Currax Pharmaceuticals, LLC. The other authors report no conflicts of interest.
CCH insight
As more people use GLP-1 medications, healthcare professionals are increasingly hearing about experiences that go beyond the most familiar side effects. Understanding how these therapies work, and how to have informed, supportive conversations with patients about what they are experiencing, is becoming an essential part of practice.
GLP-1RAs in Focus from The College of Contemporary Health is designed to help healthcare professionals strengthen their knowledge of GLP-1 receptor agonists and support patients with confidence.
Explore GLP-1RAs in Focus today →
Source: University of Pennsylvania School of Engineering and Applied Science
Read More